Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.95 Million EUR | -20.83% |
| 2022 | 3.72 Million EUR | -7.41% |
| 2021 | 4.02 Million EUR | -21.92% |
| 2020 | 5.15 Million EUR | 2.08% |
| 2019 | 5.04 Million EUR | 233.93% |
| 2018 | 1.51 Million EUR | -81.67% |
| 2017 | 8.25 Million EUR | -17.21% |
| 2016 | 9.96 Million EUR | -12.19% |
| 2015 | 11.34 Million EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.54 Million EUR | 0.0% |
| 2023 Q4 | 2.03 Million EUR | 0.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 3.39 Million EUR | 0.0% |
| 2023 Q3 | 2.03 Million EUR | -39.96% |
| 2023 FY | 2.95 Million EUR | -20.83% |
| 2022 Q2 | 3.48 Million EUR | 0.0% |
| 2022 FY | 3.72 Million EUR | -7.41% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 2.74 Million EUR | 0.0% |
| 2022 Q3 | 2.74 Million EUR | -21.21% |
| 2021 Q4 | 4.02 Million EUR | 28.32% |
| 2021 Q3 | 3.13 Million EUR | -32.24% |
| 2021 FY | 4.02 Million EUR | -21.92% |
| 2021 Q2 | 4.62 Million EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2020 FY | 5.15 Million EUR | 2.08% |
| 2020 Q2 | 4.91 Million EUR | 0.0% |
| 2020 Q3 | 3.99 Million EUR | -18.83% |
| 2020 Q4 | 5.15 Million EUR | 29.11% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q3 | 5.26 Million EUR | 10.73% |
| 2019 Q1 | 4.94 Million EUR | 497.82% |
| 2019 Q2 | 4.75 Million EUR | -3.82% |
| 2019 FY | 5.04 Million EUR | 233.93% |
| 2019 Q4 | 4.93 Million EUR | -6.32% |
| 2018 Q2 | 762 Thousand EUR | -8.74% |
| 2018 FY | 1.51 Million EUR | -81.67% |
| 2018 Q4 | 827 Thousand EUR | 14.07% |
| 2018 Q3 | 725 Thousand EUR | -4.86% |
| 2018 Q1 | 835 Thousand EUR | -20.4% |
| 2017 Q2 | 739 Thousand EUR | 160.21% |
| 2017 Q1 | 284 Thousand EUR | -16.22% |
| 2017 FY | 8.25 Million EUR | -17.21% |
| 2017 Q4 | 1.04 Million EUR | 60.89% |
| 2017 Q3 | 652 Thousand EUR | -11.77% |
| 2016 FY | 9.96 Million EUR | -12.19% |
| 2016 Q2 | 445 Thousand EUR | -10.46% |
| 2016 Q4 | 339 Thousand EUR | -13.52% |
| 2016 Q1 | 497 Thousand EUR | -9.31% |
| 2016 Q3 | 392 Thousand EUR | -11.91% |
| 2015 Q4 | 548 Thousand EUR | -8.36% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q3 | 598 Thousand EUR | -7.72% |
| 2015 Q2 | 648 Thousand EUR | 0.0% |
| 2015 FY | 11.34 Million EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 92.84% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 28.432% |
| SQZ Biotechnologies Company | 27.47 Million USD | 89.261% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 93.199% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 90.09% |
| Mesoblast Limited | 118.7 Million USD | 97.515% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -211.093% |
| Genus plc | 233.1 Million USD | 98.734% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -0.669% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -119.562% |
| Marizyme, Inc. | 18.71 Million USD | 84.239% |
| ContraFect Corporation | 2.88 Million USD | -2.395% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -293.333% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2077.331% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -103.966% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -26.83% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 47.865% |
| MultiCell Technologies, Inc. | 202.58 USD | -1456114.829% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 94.869% |
| EV Biologics, Inc. | 1.49 Million USD | -97.357% |
| Q BioMed Inc. | 4.1 Million USD | 28.224% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 91.088% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -368.197% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -140.157% |
| Biomind Labs Inc. | 735.54 Thousand USD | -301.065% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.28% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 77.302% |
| Skye Bioscience, Inc. | 4.61 Million USD | 36.082% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -232.183% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1984.54% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 49.754% |
| IMV Inc. | 28.88 Million USD | 89.787% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -11370.119% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -30.625% |
| GB Sciences, Inc. | 1.75 Million USD | -67.68% |
| Alpha Cognition Inc. | 1.22 Million USD | -141.73% |
| HST Global, Inc. | 98.31 Thousand USD | -2900.437% |
| CSL Limited | 12.18 Billion USD | 99.976% |
| Halberd Corporation | 150 Thousand USD | -1866.667% |
| Enzolytics Inc. | 996.33 Thousand USD | -196.084% |
| Resverlogix Corp. | 6.49 Million USD | 54.552% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -517.801% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1054.183% |
| argenx SE | 20 Million USD | 85.25% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 93.525% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -8.908% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -28750.856% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.294% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1370.471% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -23.033% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1186.575% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 95.639% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 2.518% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -720.105% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 85.488% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1884.474% |
| BioStem Technologies, Inc. | 4.71 Million USD | 37.386% |
| ONE Bio Corp. | 19.71 Million USD | 85.037% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1079.142% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1086.073% |
| Agentix Corp. | 50 Thousand USD | -5800.0% |
| LadRx Corporation | 33.6 Thousand USD | -8678.194% |
| Cell Source, Inc. | 9.25 Million USD | 68.122% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -290.106% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -290.106% |
| NovAccess Global Inc. | 2.19 Million USD | -34.098% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 58.291% |
| Itoco Inc. | 228.37 Thousand USD | -1191.724% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1298.27% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 40.799% |
| Kadimastem Ltd | 891.22 Thousand USD | -231.005% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -634.107% |
| CytoDyn Inc. | 30.07 Million USD | 90.192% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -509.147% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -738.433% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 62.276% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2308.163% |
| Rebus Holdings, Inc. | 310 Thousand USD | -851.613% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 37.702% |
| International Stem Cell Corporation | 4.17 Million USD | 29.392% |
| Bioxytran, Inc. | 1.92 Million USD | -53.247% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4626.579% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -35.265% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 64.526% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 65.638% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -89.652% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1000.746% |
| Neutra Corp. | 54.15 Thousand USD | -5347.227% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -61.202% |
| PureTech Health plc | 25.51 Million USD | 88.437% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -140.969% |
| IXICO plc | 472.02 Thousand USD | -524.97% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 80.969% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 95.262% |
| CSL Limited | 12.18 Billion USD | 99.976% |
| Cellectis S.A. | 92.77 Million USD | 96.82% |